ReviewTranslational gastroenterology and hepatology2019
Palliative chemotherapy in pancreatic cancer-treatment sequences.
Review in Translational gastroenterology and hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Prognostic implications of superior mesenteric vein/portal vein resection and histologic venous invasion in BR/LA PDAC after neoadjuvant therapy.Langenbeck's archives of surgery · 2026Article
- In vivo CRISPR screening identifies geranylgeranyl diphosphate as a pancreatic cancer tumor growth dependency.Molecular metabolism · 2024Article
- The effect of extracellular matrix on the precision medicine utility of pancreatic cancer patient-derived organoids.JCI insight · 2024Article
- Principles of Palliative and Supportive Care in Pancreatic Cancer: A Review.Biomedicines · 2023Review
- Article
- Precision Medicine in Pancreatitis: The Future of Acute Pancreatitis Care.Function (Oxford, England) · 2023Review
- FOLFIRINOX Pharmacodynamic Interactions in 2D and 3D Pancreatic Cancer Cell Cultures.The AAPS journal · 2022Article
- Efficacy of relative dose intensity of nab-paclitaxel for the short-term outcomes, survival, and quality of life in patients with advanced pancreatic cancer: a retrospective study.Translational cancer research · 2022Article
- Altered glycosylation in pancreatic cancer and beyond.The Journal of experimental medicine · 2022Review
- Combination therapy with low-frequency ultrasound irradiation and radiofrequency ablation as a synergistic treatment for pancreatic cancer.Bioengineered · 2021Article
- Review
- Dynamic Stromal Alterations Influence Tumor-Stroma Crosstalk to Promote Pancreatic Cancer and Treatment Resistance.Cancers · 2021Review
- Precision Therapy of Pancreatic Cancer: From Bench to Bedside.Visceral medicine · 2020Review
- Comparison between B-mode ultrasonography and contrast-enhanced ultrasonography for the surveillance of early stage pancreatic cancer: a retrospective study.Journal of gastrointestinal oncology · 2020Article
- Multivisceral resection for adenocarcinoma of the pancreatic body and tail-a retrospective single-center analysis.World journal of surgical oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer belongs to the most deadly malignancies and is expected to become the second deadliest cancer by 2040. Still, in most of the cases the tumor is detected in a nonresectable or metastatic state and, untreated, the disease will progress rapidly. Even with chemotherapeutic treatment the prognosis is poor and the 5-year overall survival rate is less than 10%. Therefore, there is a need for proper therapeutic options for the palliative treatment of the disease. Despite great efforts to find new drugs for the treatment of pancreatic cancer, for a long time the therapy was limited to the use of gemcitabine with very limited benefit. Recently new chemotherapeutic regimens have been identified that helped to improve the overall survival significantly. In addition, even second-line therapies have been established. This review will provide an overview on the current standard of care, discusses possible treatment sequences and offer a perspective on future developments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.